← Back to Search

Radiation Therapy

Stereotactic Radiosurgery for Brain Metastases

N/A

Waitlist Available

Led By Steve Burton, MD

Research Sponsored by Steven Burton

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

A life expectancy of at least 12 weeks with a Karnofsky performance status of at least 70

No prior radiotherapy to the brain

Must not have

Four or more newly-diagnosed lesions

Symptomatic patients in need of surgery to the 'target' lesion

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 3 years

Awards & highlights

Summary

This trial is testing whether fractionated stereotactic radiosurgery (FSRS) is a feasible treatment option for people with no prior whole brain radiation.

Who is the study for?

This trial is for adults with brain metastases who have not had whole brain radiation. They should be expected to live at least 12 weeks, be fairly active (Karnofsky score ≥70), and have up to 3 measurable brain lesions, one between 3-5cm. Prior chemotherapy is okay, but no prior radiotherapy or surgery on the target lesion(s). Pregnant or breastfeeding individuals are excluded.Check my eligibility

What is being tested?

The study tests fractionated stereotactic radiosurgery (FSRS) which divides the total radiation dose into smaller treatments for large brain metastases. The goal is to see if FSRS can treat larger tumors that typically wouldn't be candidates for single-dose radiosurgery.See study design

What are the potential side effects?

Potential side effects of FSRS include fatigue, headaches, hair loss at treatment site, nausea, swelling in the treated area leading to increased pressure within the skull and potential neurological issues like difficulty speaking or weakness.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am expected to live at least 12 weeks and can care for myself with some assistance.

Select...

I have not had radiation treatment to my brain.

Select...

My primary cancer is not in the brain.

Select...

I have a tumor between 3cm and 5cm suitable for targeted radiation therapy.

Select...

I have 3 or fewer distinct brain lesions.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have four or more new lesions.

Select...

I need surgery for my main cancer lesion because it's causing symptoms.

Select...

I have had surgery to remove a specific tumor.

Select...

I have had whole brain radiation therapy before.

Select...

I have a primary brain tumor.

Select...

My cancer is either lymphoma, leukemia, multiple myeloma, or a germ cell tumor.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 3 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 3 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum tolerated dose (MTD)

Secondary outcome measures

Functional Assessment of Cancer Therapy - Brain (FACT-Br)

Local control of disease

Adrenal gland hypofunction

Trial Design

1Treatment groups

Experimental Treatment

Group I: Fractionated Stereotactic RadiosurgeryExperimental Treatment1 Intervention

24 to 36 Gy in 3 fractions (8-12 Gy/fx).

0 / 11Eligibility criteria met

Find a Location

Who is running the clinical trial?

Steven BurtonLead Sponsor

3 Previous Clinical Trials

203 Total Patients Enrolled

Steve Burton, MDPrincipal InvestigatorUniversity of Pittsburgh

1 Previous Clinical Trials

173 Total Patients Enrolled

Media Library

Fractionated Stereotactic Radiosurgery (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02054689 — N/A

Brain Metastases Research Study Groups: Fractionated Stereotactic Radiosurgery

Brain Metastases Clinical Trial 2023: Fractionated Stereotactic Radiosurgery Highlights & Side Effects. Trial Name: NCT02054689 — N/A

Fractionated Stereotactic Radiosurgery (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02054689 — N/A

~2 spots leftby Jul 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.